The response of HIV-associated lymphadenopathic Kaposi sarcoma to highly active antiretroviral therapy evaluated by 18F-FDG PET/CT.
The use of PET/CT for determining systemic Kaposi sarcoma (KS) involvement and treatment response remains to be formally assessed. Pretreatment human herpes virus-8 (HHV-8) viral load may predict clinical response of KS to therapy; however, its role in treatment monitoring and correlation with PET/CT findings is unknown. We report PET/CT findings and HHV-8 viral loads of a 46-year-old man with HIV-associated lymphadenopathic KS. After treatment with highly active antiretroviral therapy, an interval PET/CT showed partial response, despite an undetectable HHV-8 viral load. Chemotherapy was initiated, and the patient achieved a complete clinical, PET/CT, and virological response. PET/CT enabled monitoring of treatment response and led to changes in management.
T8, University College London Hospitals, Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London, London, United Kingdom.
Satveer K
SK
Mankia
Robert F
RF
Miller
Simon G
SG
Edwards
Alan
A
Ramsay
Siow Ming
SM
Lee
D023241:Antiretroviral Therapy, Highly Active; D019788:Fluorodeoxyglucose F18; D015658:HIV Infections / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy; D006801:Humans; D008206:Lymphatic Diseases / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D012514:Sarcoma, Kaposi / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed; D051598:Whole Body Imaging
D019788:Fluorodeoxyglucose F18